Ashok Subramanian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ashok Subramanian has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Kefah Mokbel
The London Breast Institute, Princess Grace Hospital, London W1U 5NY, UK
4 shared publications Anup Sharma
2 shared publications- Hilary Birch
Department of Histopathology, East Surrey Hospital, Canada Avenue, Redhill, Surrey, UK
2 shared publications A. Rohatgi
Department of General Surgery, Worthing Hospital, Worthing, West Sussex, UK
1 shared publication- Adam Stacey-Clear
Department of General Surgery, East Surrey Hospital, Canada Avenue, Redhill, Surrey, UK
1 shared publication - Adam Stacey-Clear
Department of General Surgery, East Surrey Hospital, Canada Avenue, Redhill, Surrey, UK
1 shared publication
Latest Publications
- 17 June 2011
- Published by Hindawi Limited in The Breast Journal
- Vol. 17 (4) , 436-437
An Unusual Case of Scintigraphic Mapping in Invasive Carcinoma of a Cancer Patient
- 17 June 2011
- Published by Hindawi Limited in The Breast Journal
- Vol. 17 (4) , 436-437
An Unusual Case of Scintigraphic Mapping in Invasive Carcinoma of a Cancer Patient
- 1 January 2011
- Vol. 31 (1) , 23-32
Measuring IGF-1, ER-α and EGFR expression can predict tamoxifen-resistance in ER-positive breast cancer.
In vitro studies have suggested that tamoxifen resistance may be due to altered expression and downstream signalling of insulin-like growth factor-1 (IGF-1) receptor (IGF-1l), oestrogen receptor-alpha (ERα), epidermal growth factor receptor (EGFR) and HER-2. We investigated which gene expressions could predict tamoxifen resistant breast cancer. Expression of IGF-1R, IGF-1 ligand (IGF-1), ERα, EGFR and HER-2 in 91 ER-positive breast cancer tumours were measured using real-time PCR and correlated with clinical outcome. The tamoxifen resistant group (n=20) consisted of: i) tumours which were resistant to neoadjuvant tamoxifen treatment and ii) tumours which were excised from patients who later developed recurrence or metastasis during adjuvant tamoxifen treatment. These were compared with tamoxifen sensitive tumours which were surgical excision specimens from patients who did not develop recurrence/metastasis during adjuvant tamoxifen treatment. Tumours with higher IGF-1 ligand and ERα expression took longer to develop tamoxifen resistance. Tamoxifen resistant tumours had lower IGF-1 and ERα expression compared to tamoxifen-sensitive tumours. IGF-1 expression strongly correlated with ERα expression in the tamoxifen sensitive group only. ERα inversely correlated with EGFR expression in the tamoxifen resistant group only. We conclude that IGF-1 ligand and ERα expression in breast carcinomas can be measured to predict tamoxifen resistance. Measuring ERα expression using RT-PCR may be more sensitive than immunohistochemistry in determining anti-oestrogen sensitivity.
- 1 January 2011
- Vol. 31 (1) , 23-32
Measuring IGF-1, ER-α and EGFR expression can predict tamoxifen-resistance in ER-positive breast cancer.
In vitro studies have suggested that tamoxifen resistance may be due to altered expression and downstream signalling of insulin-like growth factor-1 (IGF-1) receptor (IGF-1l), oestrogen receptor-alpha (ERα), epidermal growth factor receptor (EGFR) and HER-2. We investigated which gene expressions could predict tamoxifen resistant breast cancer. Expression of IGF-1R, IGF-1 ligand (IGF-1), ERα, EGFR and HER-2 in 91 ER-positive breast cancer tumours were measured using real-time PCR and correlated with clinical outcome. The tamoxifen resistant group (n=20) consisted of: i) tumours which were resistant to neoadjuvant tamoxifen treatment and ii) tumours which were excised from patients who later developed recurrence or metastasis during adjuvant tamoxifen treatment. These were compared with tamoxifen sensitive tumours which were surgical excision specimens from patients who did not develop recurrence/metastasis during adjuvant tamoxifen treatment. Tumours with higher IGF-1 ligand and ERα expression took longer to develop tamoxifen resistance. Tamoxifen resistant tumours had lower IGF-1 and ERα expression compared to tamoxifen-sensitive tumours. IGF-1 expression strongly correlated with ERα expression in the tamoxifen sensitive group only. ERα inversely correlated with EGFR expression in the tamoxifen resistant group only. We conclude that IGF-1 ligand and ERα expression in breast carcinomas can be measured to predict tamoxifen resistance. Measuring ERα expression using RT-PCR may be more sensitive than immunohistochemistry in determining anti-oestrogen sensitivity.
- 21 August 2008
- Published by Wiley in Colorectal Disease
- Vol. 10 (7) , 673-676
The BSG/ACPGBI guidelines for colonoscopic screening: what are we missing?
Before publication of the British Society of Gastroenterology and Association of Coloproctology of Great Britain and Ireland guidelines in 2002, screening for people with a family history of colorectal cancer was sporadic and largely dependant on unvalidated local guidelines. Since 1990 we have been screening patients with both high and moderate risk family histories of colorectal cancer using local protocols which were more liberal than the new guidelines. In this study, we have analysed the pathology that would have been missed if we had been using the new guidelines in the period 1990-2002. A total of 399 consecutive patients with a positive family history of colorectal malignancy underwent screening endoscopy according to local guidelines. Demographic, endoscopic and pathologic data were prospectively collected. Patients were retrospectively divided into those who would have been screened under the new guidelines (group 1) and those who would not (group 2). The recorded pathology was graded as significant or insignificant and the findings compared between the two groups. A total of 399 patients underwent 557 endoscopies of which 278 (50%) were indicated under the new guidelines (group 1) and 279 (50%) were not indicated (group 2). A significant pathology or carcinoma was found in 15.8% of group 1 endoscopies and 10.0% of group 2 endoscopies. This difference was significant. If we had been using the new guidelines in the period 1990-2002, we would not have performed 279 (50%) of the 557 procedures, but would not have discovered significant pathology in 10% of the moderate risk endoscopies representing 39% of the significant pathology, which was actually present in this population.
- 21 August 2008
- Published by Wiley in Colorectal Disease
- Vol. 10 (7) , 673-676
The BSG/ACPGBI guidelines for colonoscopic screening: what are we missing?
Before publication of the British Society of Gastroenterology and Association of Coloproctology of Great Britain and Ireland guidelines in 2002, screening for people with a family history of colorectal cancer was sporadic and largely dependant on unvalidated local guidelines. Since 1990 we have been screening patients with both high and moderate risk family histories of colorectal cancer using local protocols which were more liberal than the new guidelines. In this study, we have analysed the pathology that would have been missed if we had been using the new guidelines in the period 1990-2002. A total of 399 consecutive patients with a positive family history of colorectal malignancy underwent screening endoscopy according to local guidelines. Demographic, endoscopic and pathologic data were prospectively collected. Patients were retrospectively divided into those who would have been screened under the new guidelines (group 1) and those who would not (group 2). The recorded pathology was graded as significant or insignificant and the findings compared between the two groups. A total of 399 patients underwent 557 endoscopies of which 278 (50%) were indicated under the new guidelines (group 1) and 279 (50%) were not indicated (group 2). A significant pathology or carcinoma was found in 15.8% of group 1 endoscopies and 10.0% of group 2 endoscopies. This difference was significant. If we had been using the new guidelines in the period 1990-2002, we would not have performed 279 (50%) of the 557 procedures, but would not have discovered significant pathology in 10% of the moderate risk endoscopies representing 39% of the significant pathology, which was actually present in this population.
- Open Access
- 28 April 2008
- Published by Springer Nature in International Seminars in Surgical Oncology
- Vol. 5 (1) , 9
The role of Herceptin in early breast cancer
Herceptin is widely regarded as the most important development in the treatment of breast cancer since Tamoxifen and the development of the multidisciplinary team (MDT). It is particularly exciting from an oncological polint of view as it represents success in the emerging field of specific targeted therapies to specific molecular abnormalities in tumour cells. This review will focus on the nature of the Her2 overexpression and the role of herceptin in the treatment of early breast cancer.
- 28 April 2008
- Published by Springer Nature in International Seminars in Surgical Oncology
- Vol. 5 (1) , 9
Open AccessThe role of Herceptin in early breast cancer
Herceptin is widely regarded as the most important development in the treatment of breast cancer since Tamoxifen and the development of the multidisciplinary team (MDT). It is particularly exciting from an oncological polint of view as it represents success in the emerging field of specific targeted therapies to specific molecular abnormalities in tumour cells. This review will focus on the nature of the Her2 overexpression and the role of herceptin in the treatment of early breast cancer.
- Open Access
- 6 March 2008
- Published by Springer Nature in Molecular Cancer
- Vol. 7 (1) , 23
Lymphangiogenesis and lymph node metastasis in breast cancer
There have been few studies on lymphangiogenesis in the past due to the lack of specific lymphatic endothelial markers, and lymphatic-specific growth factors. Recently, these limitations have been relieved by the discovery of a small number of potential lymphatic-specific markers. The relationship between lymphangiogenesis and regional or distant metastasis has not previously been investigated in humans. Using these lymphatic markers, it is possible to explore the relationship between lymphangiogenesis and tumour metastasis. This study indirectly quantified lymphangiogenesis by measuring mRNA expression of all seven lymphatic markers described above in breast cancers and correlated these markers with lymphatic involvement and survival.
- 6 March 2008
- Published by Springer Nature in Molecular Cancer
- Vol. 7 (1) , 23
Open AccessLymphangiogenesis and lymph node metastasis in breast cancer
There have been few studies on lymphangiogenesis in the past due to the lack of specific lymphatic endothelial markers, and lymphatic-specific growth factors. Recently, these limitations have been relieved by the discovery of a small number of potential lymphatic-specific markers. The relationship between lymphangiogenesis and regional or distant metastasis has not previously been investigated in humans. Using these lymphatic markers, it is possible to explore the relationship between lymphangiogenesis and tumour metastasis. This study indirectly quantified lymphangiogenesis by measuring mRNA expression of all seven lymphatic markers described above in breast cancers and correlated these markers with lymphatic involvement and survival.
- 5 July 2007
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 107 (2) , 181-194
Insulin-like growth factor binding proteins and breast cancer
- 5 July 2007
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 107 (2) , 181-194
Insulin-like growth factor binding proteins and breast cancer
- 1 June 2007
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 33 (6) , 747-750
Superficial Venous Pathology in the Asian Population of South West London – A Prospective Study
- 1 June 2007
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 33 (6) , 747-750
Superficial Venous Pathology in the Asian Population of South West London – A Prospective Study
- Open Access
- 6 May 2007
- Published by Springer Nature in International Seminars in Surgical Oncology
- Vol. 4 (1) , 12
Pagets disease of uncertain origin: case report
Pagets disease of the nipple presents as an eczematous lesion, occurs in 1 – 4% of all female breast carcinoma cases and is invariably associated with underlying malignancy either overt or occult. The majority of these cases are invasive disease although 40–45% are associated with DCIS.
- 6 May 2007
- Published by Springer Nature in International Seminars in Surgical Oncology
- Vol. 4 (1) , 12
Open AccessPagets disease of uncertain origin: case report
Pagets disease of the nipple presents as an eczematous lesion, occurs in 1 – 4% of all female breast carcinoma cases and is invariably associated with underlying malignancy either overt or occult. The majority of these cases are invasive disease although 40–45% are associated with DCIS.
- Open Access
- 3 May 2007
- Published by Springer Nature in International Seminars in Surgical Oncology
- Vol. 4 (1) , 11
An unusual cause of chest pain:case report
Sarcomas form a heterogenous group of relatively uncommon malignant tumours which are derived from connective tissue components. In total they comprise approximately 1% of all new cancers diagnosed per year in the United Kingdom (UK). As subset of this, the 'Unclassified' Sarcoma forms approximately 4% of the total 1. They often present with as relatively slow growing, asymptomatic masses and as such may often be misdiagnosed as in this case.
- 3 May 2007
- Published by Springer Nature in International Seminars in Surgical Oncology
- Vol. 4 (1) , 11
Open AccessAn unusual cause of chest pain:case report
Sarcomas form a heterogenous group of relatively uncommon malignant tumours which are derived from connective tissue components. In total they comprise approximately 1% of all new cancers diagnosed per year in the United Kingdom (UK). As subset of this, the 'Unclassified' Sarcoma forms approximately 4% of the total 1. They often present with as relatively slow growing, asymptomatic masses and as such may often be misdiagnosed as in this case.
- Open Access
- 14 February 2007
- Published by Springer Nature in International Seminars in Surgical Oncology
- Vol. 4 (1) , 4
Current management of the axilla in patients with clinically node-negative breast cancer: a nationwide survey of United Kingdom breast surgeons
- 14 February 2007
- Published by Springer Nature in International Seminars in Surgical Oncology
- Vol. 4 (1) , 4
Open AccessCurrent management of the axilla in patients with clinically node-negative breast cancer: a nationwide survey of United Kingdom breast surgeons